AOD-9604: What the Research Says About the Fat-Loss HGH Fragment
AOD-9604 is one of the most-searched fat-metabolism research peptides of 2026, and for good reason: it is a short fragment of human growth hormone engineered to isolate a single mechanism. Derived from the C-terminus of HGH (amino acids 177–191), it has drawn renewed laboratory interest as researchers look for compounds that target lipolysis without the broader hormonal effects of full-length growth hormone. This overview summarizes what the literature describes, how AOD-9604 compares to the metabolic peptides we carry, and how researchers handle it.
What AOD-9604 Is
AOD-9604 (the "anti-obesity drug" fragment) is a modified peptide based on the final 16 amino acids of the HGH molecule, with an added tyrosine to improve stability. The design goal was to retain growth hormone's fat-mobilizing signal while leaving its growth-promoting and glucose-related activity behind.
Because it is a fragment rather than a full hormone, it is often grouped with other "single-mechanism" research peptides that isolate one pathway from a larger, multi-functional molecule.
What the Research Describes
In preclinical models reported in the literature, AOD-9604 has been described as stimulating lipolysis (the breakdown of stored fat) and inhibiting lipogenesis (the formation of new fat), apparently without the diabetogenic effects associated with intact HGH.
Early-phase human trials investigated it for metabolic endpoints, but no regulatory authority recognizes AOD-9604 as an approved treatment for obesity or any other condition. The compound remains designated strictly for research use, and reported figures should be read as exploratory rather than clinical guidance.
How It Compares to Carried Metabolic Peptides
AOD-9604 itself is not currently in our catalog, but several well-studied metabolic compounds are. The incretin-based agonists work through appetite and glucose pathways rather than direct lipolysis — see Retatrutide, the triple agonist covered in our Retatrutide research overview, and Tirzepatide.
For mechanisms closer to AOD-9604's cellular-energy angle, researchers often look at MOTS-C, the mitochondrial-derived peptide, and 5-Amino-1MQ. Growth-hormone-axis comparisons frequently reference Tesamorelin, which is discussed in our Tesamorelin write-up.
Why Fragment Peptides Are Trending
The 2026 research landscape shows growing interest in fragments that separate a desired action from an unwanted one. AOD-9604 is the textbook example: it attempts to keep the fat-signaling portion of HGH while discarding the rest.
This "isolate the mechanism" approach is the same logic behind pairing distinct compounds in study designs — for instance, combining a lipolytic fragment with a centrally-acting appetite pathway to probe complementary, non-redundant targets.
Handling and Storage
Like most research peptides, AOD-9604 is typically supplied as a lyophilized (freeze-dried) powder. It is reconstituted with bacteriostatic water before use in the lab.
Lyophilized powder is generally stored cold and protected from light; reconstituted material is kept refrigerated and used within a limited window. For step-by-step mixing and volume math, see our guide to reconstituting peptides.
The Bottom Line
AOD-9604 is a compact HGH fragment studied for its lipolytic signaling in research models. It is not approved for human use and we do not currently carry it, but researchers comparing fat-metabolism pathways can explore carried alternatives across the incretin, mitochondrial, and growth-hormone-axis categories.
Research use only. This article is educational and is not medical advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.